EUCTR2010-018673-37-GB进行中（未招募）1 期
The use of Ranibizumab (Lucentis ®) for the treatment of corneal neovascularisation - Management and control of corneal neovascularisation using Lucentis
niversity of Nottingham0 个研究点目标入组 6 人开始时间: 2010年4月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients with all the below criteria:
- •- Patients over the age of 18
- •- With corneal neovascularisation non responsive or non tolerant to conventional steroid therapy
- •- And capable of consenting
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients under 18 years of age
- •- Patients unable to provide informed consent
- •- Patients who are needle phobic
- •- Patients refusing consent
- •- Pregnant women or women aiming for conception
- •- Patients with communication difficulties
- •- Patients with hypersensitivity to the active substance or to any of the excipients.
- •- Patients with active or suspected ocular or periocular infections.
- •- Patients with active severe intraocular inflammation.
研究者
相似试验
招募中
2 期
A phase II, 12 month, randomized, sham-controlled trial of ranibizumab (Lucentis) combined with grid laser compared with laser alone for the treatment of recalcitrant, diabetic macular oedema.Diabetic Macular OedemaEye - Diseases / disorders of the eyeMetabolic and Endocrine - DiabetesDiabetic RetinopathyACTRN12611000063910ovartis40
尚未招募
不适用
Establishment of a proper use of ranibizumab for the macular edema in retinal vein occlusioRetinal vein occlusionJPRN-UMIN000012188Departmant of opthalmology,Kansai Medical University50
进行中（未招募）
1 期
Ranibizumab (Lucentis) for treatment of Uveitic Macular Oedema (LIMO)veitic Macular OedemaMedDRA version: 20.0 Level: PT Classification code 10046851 Term: Uveitis System Organ Class: 10015919 - Eye disordersMedDRA version: 20.1 Level: PT Classification code 10058202 Term: Cystoid macular oedema System Organ Class: 10015919 - Eye disordersEUCTR2011-001869-41-GBMoorfields Eye Hospital NHS Foundation Trust20
尚未招募
不适用
The switching therapy with Ranibizumab for Exudative Age-related Macular Degeneration resistant to AfliberceptJPRN-UMIN000012724Department of Ophthalmology, Kagawa university faculty of medicine30
进行中（未招募）
不适用
Comparision of Ranibizumab (Lucentis) Monotherapy versus Combination of Ranibizumab (Lucentis) with Photodynamic Therapy (Verteporfin) in Patients with Subfoveal Choroidal Neovascularisation due to Age-Related Macular Degeneration - KAV-RanibizumabEUCTR2006-006760-28-ATudwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie45